Molecular Partners Selects MP0730 as CD70-Targeting Radiotherapy Candidate

PUBT · 2d ago
Molecular Partners Selects MP0730 as CD70-Targeting Radiotherapy Candidate
  • Molecular Partners selected MP0730 as its third targeted alpha radiotherapy program, targeting CD70 in kidney cancer and other cancers.
  • Preclinical data in tumor-bearing mice showed strong, sustained tumor uptake relative to healthy tissues, including the kidneys, liver and blood.
  • A first-in-human program is expected to start in the second half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Molecular Partners AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610220100PRIMZONEFULLFEED9850887) on October 22, 2026, and is solely responsible for the information contained therein.